Display options
Cite
Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. Hepat Med. 2015;7:11-20doi: 10.2147/HMER.S79584.
Janardhan, S. V., & Reau, N. S. (2015). Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. Hepatic medicine : evidence and research, 711-20. https://doi.org/10.2147/HMER.S79584
Janardhan, Sujit V, and Reau, Nancy S. "Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?." Hepatic medicine : evidence and research vol. 7 (2015): 11-20. doi: https://doi.org/10.2147/HMER.S79584
Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. Hepat Med. 2015 Apr 16;7:11-20. doi: 10.2147/HMER.S79584. eCollection 2015. PMID: 25926761; PMCID: PMC4403691.
Copy Download .nbib Format: NLM
Share it on

Hepat Med. 2015 Apr 16;7:11-20. doi: 10.2147/HMER.S79584. eCollection 2015.

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?.

Hepatic medicine : evidence and research

Sujit V Janardhan, Nancy S Reau

Affiliations

  1. Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA.

PMID: 25926761 PMCID: PMC4403691 DOI: 10.2147/HMER.S79584

Abstract

Chronic hepatitis C virus (HCV) infection represents a global health problem that affects up to 130-150 million people worldwide. The HCV treatment landscape has been transformed recently by the introduction of direct-acting antiviral (DAA) agents that target viral proteins, including the NS3 protease, the NS5B polymerase, and the NS5A protein. Treatment with multiple DAAs in combination has been shown to result in high rates of sustained virologic response, without the need for pegylated interferon, and a shorter duration of therapy compared with interferon-based regimens; however, the optimal combination of DAAs has yet to be determined. The class of NS5A inhibitors has picomolar potency with pangenotypic activity, and recent clinical studies have shown these inhibitors to be an important component of DAA combination regimens. This review discusses the rational design of an optimal anti-HCV DAA cocktail, with a focus on the role of NS5A in the HCV life cycle, the attributes of the NS5A class of inhibitors, and the potential for NS5A inhibitors to act as a scaffold for DAA-only treatment regimens.

Keywords: NS5A; direct-acting antiviral; hepatitis C virus; therapy

References

  1. N Engl J Med. 2014 Apr 17;370(16):1483-93 - PubMed
  2. PLoS Pathog. 2008 Mar 28;4(3):e1000035 - PubMed
  3. Lancet. 2014 Nov 15;384(9956):1756-65 - PubMed
  4. Nature. 2005 May 19;435(7040):374-9 - PubMed
  5. J Virol. 2004 Mar;78(6):2738-48 - PubMed
  6. N Engl J Med. 2013 May 16;368(20):1878-87 - PubMed
  7. J Biol Chem. 2012 Aug 31;287(36):30861-73 - PubMed
  8. Ann Intern Med. 2004 Mar 2;140(5):346-55 - PubMed
  9. J Virol. 2008 Aug;82(16):7964-76 - PubMed
  10. Curr Top Microbiol Immunol. 2013;369:113-42 - PubMed
  11. J Hepatol. 2013 Apr;58(4):646-54 - PubMed
  12. Hepatology. 2015 Jan;61(1):77-87 - PubMed
  13. Lancet. 2014 Aug 2;384(9941):403-13 - PubMed
  14. J Virol. 2001 Jul;75(13):6209-11 - PubMed
  15. Hepatology. 2009 Apr;49(4):1335-74 - PubMed
  16. N Engl J Med. 2014 Jan 16;370(3):211-21 - PubMed
  17. Trends Microbiol. 2011 Feb;19(2):95-103 - PubMed
  18. Hepatology. 2014 Jan;59(1):318-27 - PubMed
  19. Biochem Biophys Res Commun. 2009 Apr 17;381(4):634-8 - PubMed
  20. Hepatology. 2011 Oct;54(4):1433-44 - PubMed
  21. Virology. 1997 Apr 14;230(2):217-27 - PubMed
  22. Lancet. 2014 Aug 2;384(9941):414-26 - PubMed
  23. Int J Cancer. 2003 Oct 20;107(1):65-73 - PubMed
  24. N Engl J Med. 1997 Sep 11;337(11):725-33 - PubMed
  25. N Engl J Med. 2014 Jan 16;370(3):222-32 - PubMed
  26. Antimicrob Agents Chemother. 2002 Feb;46(2):267-74 - PubMed
  27. Curr Opin Virol. 2013 Oct;3(5):514-20 - PubMed
  28. J Biol Chem. 2005 Oct 28;280(43):36417-28 - PubMed
  29. Lancet. 2001 Sep 22;358(9286):958-65 - PubMed
  30. Expert Rev Anti Infect Ther. 2010 May;8(5):555-64 - PubMed
  31. Lancet. 2014 Nov 1;384(9954):1597-605 - PubMed
  32. Lancet. 2014 Feb 8;383(9916):515-23 - PubMed
  33. Nat Med. 2013 Jul;19(7):837-49 - PubMed
  34. J Hepatol. 2009 Jun;50(6):1142-54 - PubMed
  35. Nat Rev Microbiol. 2007 Jun;5(6):453-63 - PubMed
  36. J Hepatol. 2013 Apr;58(4):655-62 - PubMed
  37. N Engl J Med. 2013 May 16;368(20):1867-77 - PubMed
  38. Virus Res. 2012 Dec;170(1-2):1-14 - PubMed
  39. PLoS Pathog. 2013 May;9(5):e1003359 - PubMed
  40. J Virol. 2001 Jul;75(13):6095-106 - PubMed
  41. PLoS One. 2014 Jan 21;9(1):e86070 - PubMed
  42. J Virol. 2004 Apr;78(7):3480-8 - PubMed
  43. J Virol. 2010 Dec;84(24):12480-91 - PubMed
  44. Virology. 2007 Jul 20;364(1):1-9 - PubMed
  45. J Virol. 2012 May;86(9):4811-22 - PubMed
  46. PLoS Pathog. 2008 Mar 21;4(3):e1000032 - PubMed
  47. JAMA. 2013 Aug 14;310(6):591-608 - PubMed
  48. J Virol. 2009 May;83(9):4395-403 - PubMed
  49. J Biol Chem. 2004 Sep 24;279(39):40835-43 - PubMed
  50. Clin Gastroenterol Hepatol. 2013 Aug;11(8):1021-7 - PubMed
  51. J Biol Chem. 2004 Nov 19;279(47):48576-87 - PubMed
  52. Curr Top Microbiol Immunol. 2013;369:1-15 - PubMed
  53. Virology. 2002 Apr 10;295(2):272-83 - PubMed
  54. Gastroenterology. 2010 Feb;138(2):513-21, 521.e1-6 - PubMed
  55. J Biol Chem. 2011 Jun 10;286(23):20441-54 - PubMed
  56. N Engl J Med. 2011 Mar 31;364(13):1207-17 - PubMed
  57. J Exp Med. 1997 Oct 6;186(7):1077-85 - PubMed
  58. Dig Dis Sci. 2014 Dec;59(12):3043-52 - PubMed
  59. J Gen Virol. 2009 Jun;90(Pt 6):1329-34 - PubMed
  60. J Virol. 2013 Feb;87(4):2320-9 - PubMed
  61. Virology. 2002 Mar 1;294(1):94-105 - PubMed
  62. N Engl J Med. 2014 May 22;370(21):1973-82 - PubMed
  63. Curr Gastroenterol Rep. 2012 Feb;14(1):47-54 - PubMed
  64. Curr Opin Virol. 2013 Apr;3(2):129-36 - PubMed
  65. Expert Opin Pharmacother. 2013 Jun;14(9):1161-70 - PubMed
  66. Nat Cell Biol. 2007 Sep;9(9):1089-97 - PubMed
  67. N Engl J Med. 2011 Mar 31;364(13):1195-206 - PubMed
  68. N Engl J Med. 2011 Jun 23;364(25):2417-28 - PubMed
  69. J Antimicrob Chemother. 2008 Jul;62(1):1-4 - PubMed
  70. N Engl J Med. 2011 Jun 23;364(25):2405-16 - PubMed
  71. Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2 - PubMed
  72. N Engl J Med. 2002 Sep 26;347(13):975-82 - PubMed
  73. N Engl J Med. 2014 May 15;370(20):1879-88 - PubMed
  74. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6 - PubMed
  75. Oncogene. 2002 Jul 18;21(31):4801-11 - PubMed
  76. N Engl J Med. 1997 Sep 11;337(11):734-9 - PubMed
  77. Lancet. 2015 Mar 21;385(9973):1107-13 - PubMed
  78. J Virol. 2005 Mar;79(5):3187-94 - PubMed
  79. Liver Int. 2014 Feb;34 Suppl 1:79-84 - PubMed
  80. J Gen Intern Med. 2005 Aug;20(8):754-8 - PubMed
  81. Hepatology. 2014 Jun;59(6):2403-12 - PubMed
  82. N Engl J Med. 2010 Apr 8;362(14 ):1292-303 - PubMed
  83. Int J Antimicrob Agents. 2009 Dec;34(6):516-22 - PubMed
  84. Nature. 2010 May 6;465(7294):96-100 - PubMed
  85. J Gen Virol. 2004 Sep;85(Pt 9):2485-502 - PubMed
  86. World J Gastroenterol. 2014 Mar 21;20(11):2867-75 - PubMed
  87. J Virol. 2006 Nov;80(22):11305-12 - PubMed
  88. Semin Liver Dis. 2014 Feb;34(1):9-21 - PubMed
  89. Antiviral Res. 2014 Feb;102:119-47 - PubMed
  90. PLoS Pathog. 2012;8(12):e1003056 - PubMed
  91. N Engl J Med. 2013 Jan 3;368(1):34-44 - PubMed
  92. Hepatology. 2013 Apr;57(4):1333-42 - PubMed
  93. Hepatology. 2014 Jul;60(1):98-105 - PubMed

Publication Types

Grant support